Navigation Links
NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
Date:7/11/2008

for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of the completion of the Phase 1 clinical trial for NGX-1998; the potential to treat additional indications and skin locations with NGX-1998 than are currently targeted by NGX-4010; and the expected benefits of NeurogesX' potential products, including its liquid formulation product candidate NGX-1998 and its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010 or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 or NGX-1998 and the advantages of NGX-4010 or NGX-1998 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3310 Stephanie Carrington / Jason Rando

sghiglieri@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com<
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... 27, 2011 eResearchTechnology, Inc. (ERT), (Nasdaq: ... services and customizable medical devices to biopharmaceutical and ... safety and respiratory efficacy services in drug development, ... September 30, 2011.  Unless otherwise noted, all comparative ...
... VR Laboratories LLC today announced the appointment ... Officer. Kottkamp will oversee operations at VR Laboratories, ... world-class botanical consumer, medicinal food and beverage, and ... (Photo: http://photos.prnewswire.com/prnh/20111027/FL95170 ) ...
Cached Medicine Technology:ERT Reports Third Quarter 2011 Operating Results 2ERT Reports Third Quarter 2011 Operating Results 3ERT Reports Third Quarter 2011 Operating Results 4ERT Reports Third Quarter 2011 Operating Results 5ERT Reports Third Quarter 2011 Operating Results 6ERT Reports Third Quarter 2011 Operating Results 7ERT Reports Third Quarter 2011 Operating Results 8ERT Reports Third Quarter 2011 Operating Results 9ERT Reports Third Quarter 2011 Operating Results 10ERT Reports Third Quarter 2011 Operating Results 11ERT Reports Third Quarter 2011 Operating Results 12ERT Reports Third Quarter 2011 Operating Results 13Jeff Kottkamp Chosen to Lead VR Laboratories 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Drexel University ... D. Weber, MD, MS, FACP, has been appointed vice dean ... will join Drexel from The Commonwealth Medical College, where she ... dean for clinical affairs, and professor of medicine. , ... Commonwealth Medical College, Weber had a major role in many ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... sent patients to designated cardiac receiving centers dramatically increased ... in Arizona, according to a study published online yesterday ... , "We knew lives would be saved if the ... arrest care and we were able to get cardiac ... done for Level 1 trauma patients," said lead study ...
(Date:7/25/2014)... Parkulture is proud to ... parkour instructor, Jared “JJ” Woods, will be competing on ... Ninja Warrior. The show will premiere on local affiliates ... rerun on the new Esquire Network on Tuesday, July ... has been balancing careers as a professional stuntman for ...
(Date:7/25/2014)... 2014 In today’s technological era, every ... supporting devices. This benefits the organization in various ways. ... attacks which can destroy the confidential information and processes ... and Compliance (EGRC) manage and protect the enterprise from ... cause loss in dollars to the comp may. The ...
Breaking Medicine News(10 mins):Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6
... may be the way to make a living, but it ... new study from the Universit de Montral, office-workers have become ... activity may partly explain the rise in obesity. Their findings, ... , may have health implications for the millions of people ...
... , MONDAY, Oct. 4 (HealthDay News) -- Children whose ... brain chemical serotonin because of gene mutations may be ... later in life, Norwegian researchers report. Serotonin ... important role during development, especially in the development of ...
... of chronic diseases to the top of the EU ... Kidney Health , the EU Diabetes Working Group and ... the European Parliament, together with representatives of health professionals and ... these chronic diseases urgently, they threaten the "Europe 2020 strategy", ...
... CHANGES , The use of a nasal continuous positive ... may cause craniofacial changes in adults with obstructive sleep ... Vancouver, BC, Canada, analyzed baseline and follow-up radiographs from ... for a minimum of 2 years. Changes in craniofacial ...
... SAN FRANCISCO Implementing a Medical Home practice model ... provide comprehensive care to more patients, and to offer ... with their doctors, recommendations and reduce emergency room visits ... 4, 2010, at the American Academy of Pediatrics (AAP) ...
... -- A new vaccine added to standard therapy appears to ... the most deadly form of brain cancer, according to a ... University of Texas MD Anderson Cancer Center. The vaccine ... most aggressive form of the disease. "About a third ...
Cached Medicine News:Health News:Is your job making you fat? 2Health News:New Clues to Possible Genetic Basis for ADHD 2Health News:New Clues to Possible Genetic Basis for ADHD 3Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 2Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 3Health News:Chest news briefs: CPAP may cause facial changes 2Health News:Medical home care approach improves efficiency and care at clinic for low-income families 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 3
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Medicine Products: